

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/radcr



Case Report

Delayed bronchial obstruction following esophageal stent placement: A case report and review of the literature *

Seth Arntz, BSc*, Luke Roller, MD

Department of Radiology, University of North Dakota School of Medicine and Health Sciences, 701 E Rosser Ave, Bismarck, ND 58501-4461, USA

ARTICLE INFO

Article history: Received 21 March 2023 Revised 28 May 2023 Accepted 2 June 2023

Keywords:

Esophageal adenocarcinoma Esophageal stent placement Delayed bronchial obstruction Airway compromise

ABSTRACT

Esophageal adenocarcinoma typically has a poor prognosis at the time of diagnosis. Consequently, palliation of symptoms is vital to disease management with a cornerstone for palliation being esophageal stent placement. Esophageal stents are associated with a variety of complications that may present immediately or long after stent placement is completed. In this report, we present a 58-year-old male who developed shortness of breath 4 months after metallic esophageal stent placement. After further evaluation with a chest radiograph and CT angiogram of the chest, the patient was found to have obstruction of the left mainstem bronchus secondary to mass effect from the esophageal stent. Airway compromise secondary to metallic esophageal stent placement typically occurs immediately after placement of the stent. There are only a few documented cases of this complication occurring at a delayed interval. This case clearly demonstrates this rare complication of esophageal stent placement in the setting of esophageal adenocarcinoma.

© 2023 The Authors. Published by Elsevier Inc. on behalf of University of Washington.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Self-expanding metallic stents (SEMS) are typically utilized in those with dysphagia or obstruction secondary to a malignant process, most commonly esophageal adenocarcinoma (EAC). SEMS were first used in 1990 for relieving symptoms of malignant esophageal obstruction and since that time have become a cornerstone in the palliation of symptoms of esophageal malignancy [1–3]. SEMS placement has been shown to pro-

vide immediate improvement of dysphagia in 80%-85% of patients, which is more effective than plastic stents which show improvement in 62%-69% of patients [1,4]. Furthermore, SEMS have a reduced risk of causing stent-related mortality (14%) as compared to plastic stents (29%) [1,4,5].

Metallic esophageal stents may be covered, partially covered, or uncovered [6]. Generally, covered and partially covered stents are more prone to migration but less prone to tumor ingrowth and are more easily removed [6,7]. Comparatively, un-

E-mail address: setharntz@gmail.com (S. Arntz).

^{*} Competing Interests: The authors have declared that no competing interests exist.

^{*} Corresponding author.




Fig. 1 – AP chest radiograph completed shortly after placement of 2 esophageal SEMS which demonstrated appropriate positioning.

covered stents are less prone to migration but are more likely to have tumor ingrowth and often cannot be removed [6].

A variety of complications may occur secondary to covered SEMS placement, including those which are lifethreatening [8]. The most common complications associated with esophageal stents can be grouped into immediate, early, and delayed manifestations. Immediate complications occur during implantation of the device and include perforation, stent malposition, and respiratory tract compression. Early complications are characterized as occurring within 1 week of implantation of an esophageal stent and include bleeding, chest pain, fever, gastroesophageal reflux, globus sensation, perforation, and stent migration [6,8]. Delayed complications occur later than 1 week following stent placement and include stent migration, stent occlusion, tumor ingrowth, development of esophageal fistulae, and recurrence of strictures [6,8]. The most common complication of covered SEMS is stent migration, with a frequency of 36.3% [9]. Other common complications include pain, obstruction, and bleeding. Notably, overall stent related mortality in the first 24 hours following insertion is 1.7% [10].

Case report

At a small, rural hospital, a 58-year-old male presented with a worsening cough and shortness of breath for 2 days. Past medical history was significant for esophageal adenocarcinoma status post chemotherapy, radiation, and 2 SEMS placements approximately 4 months prior (Fig. 1). Associated symptoms included generalized weakness, anorexia, diarrhea, and chest pain with coughing. On examination, the patient's breath sounds were decreased bilaterally. Laboratory studies were significant for 15.9 white blood cells and a D-dimer of 737.




Fig. 2 – PA chest radiograph shows the esophageal stent (green arrow) and interval loss of visualization of the normally air filled left mainstem bronchus (red arrows). There is associated new left side pulmonary volume loss and new left sided consolidative pulmonary opacities.

A chest x-ray showed significant left lower lobe consolidative opacities and developing consolidative opacities in the right upper and right lower lobes (Fig. 2). Due to concern for a pulmonary embolism, a CTA chest was ordered that showed a patent esophageal stent with mass effect causing significant extrinsic narrowing of the proximal left mainstem bronchus with significant consolidative opacities in the left lung (Figs. 3 and 4). The patient was then transferred to a larger regional hospital.

Following arrival, the 2 esophageal stents were removed by a gastroenterologist who noted significant esophageal erosions. Following the procedure, the patient continued to be illappearing and required increased oxygen supplementation. The patient was placed on NPO orders for 2 days and then transitioned to clear liquids. He immediately aspirated fluid with this trial and was transitioned back to NPO status. A follow-up CT chest with IV contrast showed moderate improvement of the extrinsic narrowing of the left mainstem bronchus and improved left lung consolidation. However, the follow up CT also demonstrated a tracheoesophageal fistula and a left main bronchoesophageal fistula (Figs. 5 and 6).

These findings were discussed with the patent. Given the limited further oncologic treatment available, he decided to pursue palliative care only.

Discussion

Respiratory tract compression leading to airway compromise is a potentially fatal outcome of SEMS placement. Immediate airway compromise during or shortly after esophageal stenting occurs in 0%-2% [4,8] of cases. However, our case demonstrated a delayed presentation of airway compromise




Fig. 3 – CTA chest coronal view shows obstruction of the proximal left main bronchus and postobstructive consolidative opacities in the ligula. The extrinsic compression from the esophageal stent causing the obstruction is not well seen in this view.




Fig. 4 – CTA chest axial view demonstrates that the esophageal stent (green arrow) extrinsically compresses and occludes the left mainstem bronchus (red arrows). There are significant postobstructive consolidative opacities in the left lung.

4 months after the placement of an esophageal stent. There is no known data available on either incidence or mortality of this delayed complication.

Delayed-onset bronchial obstruction is an exceptionally rare complication following SEMS placement with only a few cases reported in the literature [5,11]. It is a poorly studied phenomenon with risk factors being unknown; however, it is pos-




Fig. 5 – Patient is status post esophageal stent removal. Axial CT demonstrates a tracheoesophageal fistula (red arrow).



Fig. 6 – Axial CT also demonstrates a bronchoesophageal fistula (red arrow).

sible there is an overlap of the predisposing factors that are associated with immediate onset airway compromise. Several of these important factors include stent position, history of irradiation, and associated mediastinal mass [12,13].

The most important factor in immediate onset airway compromise is proximal positioning of the stent in the esophagus at or above the level of the carina. Furthermore, there is evidence to suggest that a history of radiation is associated with an increased number of severe complications of stent placement [12,14]. Lastly, increasing size of a mediastinal mass appears to be associated with an increased risk for airway compromise secondary to stent placement [13]. We were not able to locate any statistics on the relative risks associated with these risk factors.

A potential management option in a patient with delayed airway obstruction secondary to SEMS placement includes tracheobronchial stenting, although this may both be technically difficult depending on the degree of airway obstruction [5,13]. Alternatively, removal of the esophageal stent(s) is an option, though this may limit long-term prognosis without further intervention [13]. Due to the infrequency of this delayed complication, we were unable to find statistics on the efficacy of either management option.

Conclusions

Esophageal stenting is an important source of palliation in those with esophageal malignancy. Self-expanding metal stents are associated with a variety of complications including bronchial airway obstruction. We present a rare case of delayed bronchial airway obstruction occurring 4 months after esophageal stent placement.

Patient consent

Written informed consent for the publication of this case report was obtained from the patient.

REFERENCES

- Yim HB. Self-expanding metallic stents and self-expanding plastic stents in the palliation of malignant oesophageal dysphagia. Ann Palliat Med 2014;3(2):41–6. doi:10.3978/j.issn.2224-5820.2014.03.03.
- [2] Kim KY, Tsauo J, Song HY, Kim PH, Park JH. Self-expandable metallic stent placement for the palliation of esophageal cancer. J Korean Med Sci 2017;32(7):1062–71. doi:10.3346/jkms.2017.32.7.1062.
- [3] Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology 2015;149(2):302–17 e1. doi:10.1053/j.gastro.2015.04.053.

- [4] Christie NA, Buenaventura PO, Fernando HC, Alijani A, Rao C, Darzi A, et al. Results of expandable metal stents for malignant esophageal obstruction in 100 patients: short-term and long-term follow-up. Ann Thorac Surg 2001;71(6):1797–802. doi:10.1016/s0003-4975(01)02619-4.
- [5] Kim S, Choi H, Keum B. Delayed bronchial obstruction following esophageal stent implantation: a case report. Medicina (B Aires) 2022;58(2):231. doi:10.3390/medicina58020231.
- [6] Hindy P, Hong J, Lam-Tsai Y, Gress F. A comprehensive review of esophageal stents. Gastroenterol Hepatol (N Y) 2012;8(8):526–34.
- [7] Wang C, Wei H, Li Y. Comparison of fully-covered vs partially covered self-expanding metallic stents for palliative treatment of inoperable esophageal malignancy: a systematic review and meta-analysis. BMC Cancer 2020;20(1):73. doi:10.1186/s12885-020-6564-6.
- [8] Kujawski K, Stasiak M, Rysz J. The evaluation of esophageal stenting complications in palliative treatment of dysphagia related to esophageal cancer. Med Sci Monit 2012;18(5):CR323–9. doi:10.12659/msm.882739.
- [9] So H, Ahn JY, Han S, Jung K, Na HK, Lee JH, et al. Efficacy and safety of fully covered self-expanding metal stents for malignant esophageal obstruction. Dig Dis Sci 2018;63(1):234–41. doi:10.1007/s10620-017-4839-9.
- [10] Yakoub D, Fahmy R, Athanasiou T, Alijani A, Rao C, Darzi A, et al. Evidence-based choice of esophageal stent for the palliative management of malignant dysphagia. World J Surg 2008;32(9):1996–2009. doi:10.1007/s00268-008-9654-1.
- [11] Dasgupta A, Jain P, Sandur S, Dolmatch BL, Geisinger MA, Mehta AC. Airway complications of esophageal self-expandable metallic stent. Gastrointest Endosc 1998;47(6):532–5. doi:10.1016/s0016-5107(98)70258-5.
- [12] Park JY, Shin JH, Song H-Y, Yi SY, Kim JH. Airway complications after covered stent placement for malignant esophageal stricture: special reference to radiation therapy. Am J Roentgenol 2012;198(2):453–9. doi:10.2214/ajr.10.5780.
- [13] Baron TH. Minimizing endoscopic complications: endoluminal stents. Gastrointest Endosc Clin N Am 2007;17(1) 83-vii. doi:10.1016/j.giec.2007.01.004.
- [14] Yakami M, Mitsumori M, Sai H, Nagata Y, Hiraoka M, Nishimura Y. Development of severe complications caused by stent placement followed by definitive radiation therapy for T4 esophageal cancer. Int J Clin Oncol 2003;8(6):395–8. doi:10.1007/s10147-003-0356-2.